- Home
- GPAT vs XOMA Comparison
GPAT vs XOMA Comparison
Compare GPAT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPAT
- XOMA
- Stock Information
- Founded
- GPAT 2020
- XOMA 1981
- Country
- GPAT United States
- XOMA United States
- Employees
- GPAT N/A
- XOMA N/A
- Industry
- GPAT
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- GPAT
- XOMA Health Care
- Exchange
- GPAT NYSE
- XOMA Nasdaq
- Market Cap
- GPAT 365.5M
- XOMA 300.5M
- IPO Year
- GPAT 2024
- XOMA N/A
- Fundamental
- Price
- GPAT $10.57
- XOMA $24.05
- Analyst Decision
- GPAT
- XOMA Strong Buy
- Analyst Count
- GPAT 0
- XOMA 2
- Target Price
- GPAT N/A
- XOMA $69.50
- AVG Volume (30 Days)
- GPAT 159.0K
- XOMA 40.4K
- Earning Date
- GPAT 01-01-0001
- XOMA 08-12-2025
- Dividend Yield
- GPAT N/A
- XOMA N/A
- EPS Growth
- GPAT N/A
- XOMA N/A
- EPS
- GPAT 0.36
- XOMA N/A
- Revenue
- GPAT N/A
- XOMA $42,909,000.00
- Revenue This Year
- GPAT N/A
- XOMA $70.91
- Revenue Next Year
- GPAT N/A
- XOMA $14.00
- P/E Ratio
- GPAT $29.58
- XOMA N/A
- Revenue Growth
- GPAT N/A
- XOMA 638.41
- 52 Week Low
- GPAT $9.98
- XOMA $18.35
- 52 Week High
- GPAT $10.64
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- GPAT N/A
- XOMA 45.38
- Support Level
- GPAT N/A
- XOMA $23.51
- Resistance Level
- GPAT N/A
- XOMA $24.65
- Average True Range (ATR)
- GPAT 0.00
- XOMA 1.10
- MACD
- GPAT 0.00
- XOMA -0.17
- Stochastic Oscillator
- GPAT 0.00
- XOMA 20.92
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.